Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age

Phase 4

Active, not recruiting

Conditions: Hunter Syndrome

Interventions: Drug: Elaprase for intravenous (IV) infusion

First Posted Date: 2015-05-28

Last Posted Date: 2024-12-17

Lead Sponsor: Shire

Target Recruit Count: 21

Registration Number: NCT02455622

Locations: 🇲🇾
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
🇷🇸
Mother and Child Health Care Institute of Serbia Dr Vukan Cupic, Beograd, Serbia
🇹🇭
Chulalongkorn University, Bangkok, Thailand

and more 5 locations

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Phase 3

Completed

Conditions: Pediatric Hypertension

Interventions: Drug: Azilsartan

First Posted Date: 2015-05-21

Last Posted Date: 2016-04-07

Lead Sponsor: Takeda

Target Recruit Count: 6

Registration Number: NCT02451150

Single-Dose Phase 1 Study of TAK-792

Phase 1

Completed

Conditions: Healthy Male Adults Participants

Interventions: Drug: TAK-792 30 mg
Drug: TAK-792 30 mg placebo
Drug: TAK-792 100 mg
Drug: TAK-792 100 mg placebo
Drug: TAK-792 250 mg
Drug: TAK-792 250 mg placebo
Drug: TAK-792 500 mg
Drug: TAK-792 500 mg placebo
Drug: TAK-792 750 mg
Drug: TAK-792 750 mg placebo
Drug: TAK-792 1250 mg
Drug: TAK-792 1250 mg placebo

First Posted Date: 2015-05-19

Last Posted Date: 2019-03-19

Lead Sponsor: Takeda

Target Recruit Count: 72

Registration Number: NCT02448719

MLN3126 Single Rising Dose Study

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: MLN3126
Drug: MLN3126 Placebo

First Posted Date: 2015-05-18

Last Posted Date: 2015-08-05

Lead Sponsor: Takeda

Target Recruit Count: 39

Registration Number: NCT02447458

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

Phase 1

Withdrawn

Conditions: Pediatric Gastroesophageal Reflux Disease

Interventions: Drug: Dexlansoprazole

First Posted Date: 2015-05-13

Last Posted Date: 2020-04-15

Lead Sponsor: Takeda

Registration Number: NCT02442752

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇲🇽
Centro de Investigacion Clinica Acelerada, S.C., Mexico, Distrito Federal, Mexico
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 19 locations

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TAK-648
Drug: Placebo

First Posted Date: 2015-04-30

Last Posted Date: 2016-08-31

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT02430870

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

Phase 4

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: Leuprorelin

First Posted Date: 2015-04-28

Last Posted Date: 2022-03-16

Lead Sponsor: Takeda

Target Recruit Count: 307

Registration Number: NCT02427958

Phase 1 Single Subcutaneous Dose Study of MLN1202

Phase 1

Withdrawn

Conditions: Healthy Japanese and Caucasian Male Adults

Interventions: Drug: MLN1202
Drug: MLN1202 Placebo

First Posted Date: 2015-04-24

Last Posted Date: 2016-10-27

Lead Sponsor: Takeda

Registration Number: NCT02426021

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab

First Posted Date: 2015-04-23

Last Posted Date: 2018-09-14

Lead Sponsor: Takeda

Target Recruit Count: 101

Registration Number: NCT02425111

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

Phase 2

Completed

Conditions: Dengue Fever

Interventions: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Biological: Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)

First Posted Date: 2015-04-23

Last Posted Date: 2019-08-28

Lead Sponsor: Takeda

Target Recruit Count: 351

Registration Number: NCT02425098

Locations: 🇸🇬
Changi General Hospital, Singapore, Singapore
🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
🇸🇬
Singapore General Hospital, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy